By Prue Salasky
12:14 PM AKDT, July 18, 2012
On Monday, the U.S. Food and Drug Administrationannounced it had approved the drug combination of 300 mg tenofovir and 200 mg emtricitabine (TDF/FTC; brand name Truvada) for daily use by uninfected adults to help prevent the sexual acquisition of HIV.
TDF/FTC has been commercially available as an HIV treatment since 2004. This is the first time any drugs have been approved for the prevention of sexually acquired HIV infection.
Dr. Kevin Fenton, Director, CDC National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention said:
"With 50,000 new HIV infections in the United States each year, additional prevention methods are urgently needed. The Centers for Disease Control and Prevention applauds the U.S. Food and Drug Administration’s decision to approve the use of Truvada (a combination of 300 milligrams of tenofovir and 200 milligrams of emtricitabine) to reduce the risk of acquiring HIV. We believe this is an important step that should help ensure that physicians and patients receive the detailed information and educational materials needed to most effectively use this prevention strategy.
If delivered effectively and targeted to those at highest risk, pre-exposure prophylaxis (PrEP) could play an important role in our response to the HIV epidemic. Strong research evidence indicates that PrEP, when used consistently, is safe and effective at reducing the risk of acquiring HIV sexually. Last year, the Centers for Disease Control and Prevention provided interim guidance for gay and bisexual men who may be considering the use of PrEP, and soon will publish similar guidance for heterosexual men and women. Key considerations for the use of PrEP include:
For more health news, go to www.dailypress.com/health